Filana Therapeutics (FLNA) vs Werewolf Therapeutics (HOWL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Werewolf Therapeutics (HOWL) has outperformed Filana Therapeutics (FLNA) over the past year, losing 51.6% versus a loss of 79.6%. Over five years, HOWL leads with a -94.7% price change compared with -98.4% for FLNA. Werewolf Therapeutics is the larger company by market cap ($44.2 million vs $39.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FLNA | HOWL |
|---|---|---|
| Share price | $0.8136 | $0.91 |
| Market cap | $39.30M | $44.23M |
| 1-day change | -0.26% | -1.10% |
| YTD return | -58.91% | +43.53% |
| 1-year return | -79.56% | -51.60% |
| 5-year return | -98.36% | -94.67% |
| EPS (TTM) | $-0.87 | $-0.73 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $1.94 |
| 52-week low | $0.67 | $0.27 |
| Distance from 52-week high | -83.66% | -53.02% |
| Analyst consensus | none | none |
| Avg. price target upside | +698.92% | +669.23% |
| Average volume | 2.03M | 6.80M |
| Shares outstanding | 48.31M | 48.60M |
| Employees | 17 | 39 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HOWL has outperformed FLNA by 28.0 percentage points over the past year.
About Filana Therapeutics
FLNA stock →Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood.
Healthcare · Biotechnology · 17 employees
About Werewolf Therapeutics
HOWL stock →Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform.
Healthcare · Biotechnology · 39 employees
FLNA vs HOWL FAQ
Which is bigger, Filana Therapeutics or Werewolf Therapeutics?
Werewolf Therapeutics (HOWL) is larger, with a market capitalization of $44.23M compared with $39.30M for Filana Therapeutics (FLNA).
Which stock has performed better over the past year, FLNA or HOWL?
HOWL returned -51.60% over the past 12 months, compared with -79.56% for FLNA (price return, excluding dividends). Past performance does not predict future results.
Are Filana Therapeutics and Werewolf Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.